High-Dose Spinal Cord Stimulation Reduces Long-Term Pain Medication Use in Patients With Failed Back Surgery Syndrome Who Obtained at Least 50% Pain Intensity and Medication Reduction During a Trial Period: A Registry-Based Cohort Study

Goudman, Lisa; Smedt, Ann De; Forget, Patrice; Eldabe, Sam; Moens, Maarten

doi:10.1111/ner.13363

Cited by 10 publications

(9 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis previously denoted that SCS results in a higher prevalence of patients at work compared with the situation before SCS (OR 2.15, 95% CI 1.44-3.21) [24]; however, the percentages of patients that effectively resumed work after SCS ranged between 10% [25] and 47% [26]. On the contrary, healthcare providers were more prone to select a reduction in pain medication use as a factor that is influenced by SCS, a finding that is completely in line with recent findings in the literature [27,28].…”

Section: Discussionsupporting

confidence: 86%

Goals, Expectations, and the Definition of Success for Neuromodulation for Pain According to Representatives of Neuromodulation Device Manufacturers

Moens

Alliet

Billot

et al. 2022

JPM

Self Cite

View full text Add to dashboard Cite

Representatives of neuromodulation device manufacturers are expected to facilitate the relationship between patients and healthcare providers. Nevertheless, the goals, expectations, and definition of success for neuromodulation for pain have not yet been explored. Representatives present at the 2nd Joint Congress of the INS European Chapters in September 2021 completed a survey to ascertain their opinions about the goals to achieve with neuromodulation, the factors that they expect to change, and their definition of success for neuromodulation. In total, 39 representatives completed the survey. To provide excellent service for patients (22.4%), to become a trusted partner for physicians (21.5%), and to provide excellent service for physicians (20.7%) were the highest ranked goals. The most frequently reported factors that were expected to change were pain intensity (23.1%), patient satisfaction (19.7%), mobility/functioning (14.5%), and capacity to return to work (13.7%). Within the definitions of success, increased quality of life of the patient was stated in 21% of the definitions, closely followed by pain control (19.3%) and happiness/patient satisfaction (15.8%). The goals of representatives of neuromodulation device manufacturers seem to focus on ensuring a good relationship with physicians on the one hand and providing good service towards patients on the other hand, whereby pain control, quality of life, and patient satisfaction seem to be important for company representatives.

show abstract

Section: Discussionsupporting

confidence: 86%

Goals, Expectations, and the Definition of Success for Neuromodulation for Pain According to Representatives of Neuromodulation Device Manufacturers

Moens

Alliet

Billot

et al. 2022

JPM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similar results were revealed in another study that women reported no pain relief after 2 hours compared to men because of the influence of estrogen or other sex hormones on COX-2; however, further investigation is necessary. 14 In the present study, the mean value of the male reporting pain decreased slightly more swiftly than the females; however, there was no significant difference appreciated between the genders.…”

Section: Discussioncontrasting

confidence: 63%

“…13 Few studies assessed the effect of preoperative administration of the NSAIDS and gabapentin drug that displayed an immediate pain relief after wearing off the anesthesia compared to the postoperative administration. 14 Nevertheless, in the present study presented effectiveness with combination therapy of gabapentin with naproxen to provide pain relief with minimum side effects of individual drugs at 24 hours period. Therefore, signifies that initially, the gabapentin did not have an immediate effect; however, its effect was evident after a 12hr period.…”

Section: Discussionmentioning

confidence: 65%

Comparison of naproxen and combination therapy (naproxen and gabapentin) in post extraction pain relief.

Khahro

Tareen²,

Soomra³

et al. 2022

TPMJ

View full text Add to dashboard Cite

Objective: To evaluate the efficacy of using combination drug treatment to relieve post extraction pain of impacted mandibular third molar by using Naproxen plus Gabapentin versus Naproxen alone. Study Design: Randomized Control study. Setting: Dental Clinic OPD of Bhitai Dental and Medical College, Sindh, Pakistan. Period: 1st December 2018 to 30th May 2019. Material & Methods: The procedure for extraction was carried out under Local Anaesthesia (2% lignocaine hydrochloride with 1:100,000 adrenaline) at dental clinic OPD of Bhitai Dental and Medical College. Some extractions were performed in Closed Extraction technique while in some patients standard surgical procedure was used which consist of triangular muco – periosteal flap on buccal surface and lingual retraction of soft tissue followed by bone removal. For Pre – Operative and 24-Hour Post – Operative Pain status assessment Visual Analogue Scale and Wong Baker’s Face Pain Rating Scale. Results: Combination therapy (Naproxen and Gabapentin) was effective in significant pain reduction at 12 Hour and 24-Hour Post Extraction period. With 26 patients out 31 presented with Pain Scale of 0 on combination therapy while only 3 out of 31 for naproxen alone after 24 hours. All patients received a single dose of study medicines from the hospital pharmacy. In demographic data, there were 47% (n=29) males and 53% (n=33) females with mean age group of 27.89. Comparing the pain response between the genders, males presented slightly faster pain relief with time as to the females. Conclusion: Enhanced effect of combination therapy of naproxen with gabapentin in reducing post extraction pain of impacted mandibular third molar with respect to naproxen alone.

show abstract

“…12 In this study, an in-hospital detoxification protocol of 8 days was used, which is in contrast to the slow forms of tapering, typically applying a tapering of 5-20% every four weeks 38 . Since the majority of patients eligible to SCS generally requires high opioid consumption due to high pain intensity scores and since SCS is able to stabilize or decrease opioid usage (but not always completely omit opioid use) 6,7,39 , the risks of continuing the opioid outweigh the risks of a rapid taper wherefore the choice was made to use a faster tapering protocol. The disadvantage of this protocol is that clonidine was needed for withdrawal symptoms, which might have been omitted if a slower tapering protocol was used 38 .…”

Section: Discussionmentioning

confidence: 99%

Detoxification of Neuromodulation-Eligible Patients by a Standardized Protocol: A Retrospective Pilot Study

Jerjir

Goudman

Buyten

et al. 2022

Neuromodulation: Technology at the Neural Interface

Self Cite

View full text Add to dashboard Cite

High-Dose Spinal Cord Stimulation Reduces Long-Term Pain Medication Use in Patients With Failed Back Surgery Syndrome Who Obtained at Least 50% Pain Intensity and Medication Reduction During a Trial Period: A Registry-Based Cohort Study

Cited by 10 publications

References 36 publications

Goals, Expectations, and the Definition of Success for Neuromodulation for Pain According to Representatives of Neuromodulation Device Manufacturers

Goals, Expectations, and the Definition of Success for Neuromodulation for Pain According to Representatives of Neuromodulation Device Manufacturers

Comparison of naproxen and combination therapy (naproxen and gabapentin) in post extraction pain relief.

Detoxification of Neuromodulation-Eligible Patients by a Standardized Protocol: A Retrospective Pilot Study

Contact Info

Product

Resources

About